Celldex Therapeutics
CLDX
Celldex Therapeutics (CLDX) news
Recent news
CellDex 2Q loss/share 94c, est. loss/share $1.07
AInvest Wire · Aug 6, 2026CellDex Therapeutics Q2 net income USD -73.503 million vs. IBES estimate USD -81.2 million
AInvest Wire · Aug 6, 2026CellDex Therapeutics Inc: Morgan Stanley cuts target price to $40.00 from $44.00
Morgan Stanley has revised its price target for CellDex Therapeutics Inc (NASDAQ: CLDX), lowering it to $40.00 from the previous $44.00, according to a recent analyst note. The adjustment reflects a reassessment of the company’s near-term outlook and market dynamics. The firm maintains its existing…
AInvest Wire · Jul 22, 2026CellDex Therapeutics Inc: Leerink Partners cuts target price to $70 from $78
AInvest Wire · Jul 22, 2026CellDex shares drop 9% after Barzolvolimab data disappoints
AInvest Wire · Jul 21, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.